{"prompt": "['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 25 of 115', 'Cardiac perforation, tamponade or pericardial effusion (within 7 days of ablation procedure)', 'Pulmonary vein stenosis (> 75% reduction within 12-months of ablation procedure)', 'Myocardial infarction (within 7 days of ablation procedure)', 'Phrenic nerve injury (unresolved at 12-months)', 'Atrio-esophageal fistula (within 12-months of ablation procedure)', 'Death (within 7 days of ablation procedure)', '7.2.2.', 'Secondary Endpoint', 'Demonstrate an improvement in quality of life between baseline and 12 months after the index ablation', 'procedure as measured by the AFEQT and SF-12 questionnaires.', 'The (AFEQT) and (SF-12) questionnaires will be utilized for this objective. The AFEQT questionnaire', 'is an atrial fibrillation specific health-related quality of life questionnaire to assess the impact of AF', \"on a subject's life. The overall score ranges from o - 100, where o corresponds to complete disability\", 'and 100 corresponds to no disability. The SF-12 questionnaire is a quality of life questionnaire that', \"evaluates the subject's mental and physical performance. Physical and mental health composite\", 'scores are calculated using responses to 12 questions with a response range from 0 to 100, where a', '0 score indicates the lowest level of health measured by the scale and 100 indicates the highest level', 'of health.', '7.2.3.', 'Ancillary Enppoints', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 26 of 115', '8. Study Design', 'Medtronic, Inc. is sponsoring the STOP Persistent AF Study; a prospective, interventional, multi-center, non-', 'randomized, single arm, unblinded clinical study. The study design diagram is shown in Figure 1.', 'Up to 225 subjects will be enrolled world-wide. In the US, Canada and Europe, up to 200 subjects will be', 'enrolled to ensure 150 subjects are treated with an Arctic Front Advance Cardiac CryoAblation Catheter.', 'The maximum number of subjects treated at Canadian and European centers combined is 45 subjects.', 'Up to 25 subjects will be enrolled in Japan to ensure15 subjects are treated with an Arctic Front Advance', 'Cardiac CryoAblation Catheter. The maximum number of subjects treated at Japanese centers is 15', 'subjects.', 'It is anticipated that at least 165 Arctic Front Advance Cardiac CryoAblation Catheters will be used in this', 'study. The maximum number of subjects that may be treated at a single center is 15 subjects (10% of the', 'total treated in the PMA-S cohort).', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 27 of 115', 'Figure 1: Study Design Flowchart', 'Eligibility Criteria Met and Patient', 'Sub-study', 'Informed Consent Form Signed', 'Baseline Data Collected', 'Cryoballoon Ablation', 'Procedure', 'Hospital Discharge', '6 week phone call', '3 Month Follow-up Visit', 'Sub-study', '6 and 12 Month Follow-up', 'Visits with Holter monitoring', 'Exit Subject', '8.1. Duration', 'Subjects from all geographies will be followed for 12 months after the index cryoballoon ablation procedure', 'and then be exited from the study. Accordingly, the expected total study duration is approximately 2 years', 'and 2 months, representing 14 months of enrollment and 12 months of subject follow-up. Subjects will not', 'be replaced with newly enrolled subjects upon early study exit. The objectives will be analyzed for a', 'Premarket Approval Supplement (PMA-S) after all subjects from the US, Canada and Europe complete 12', 'months of follow-up after the index ablation procedure. Study data from the Japanese centers will not be', 'included in the PMA-S submission. A final report will be submitted to Japan PMDA at the completion of the', 'study.', 'Version 4, 10NOVO016', 'Confidential']\n\n###\n\n", "completion": "END"}